1,616 results on '"Khoo, Saye"'
Search Results
202. Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy
203. Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity
204. Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation
205. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients
206. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.)
207. Mobilization of systemic CCL4 following HIV preexposure prophylaxis in young men in Africa.
208. Relating CYP2B6 Genotype and EFV Resistance Among Women Living With HIV With High Viremia in Uganda: A Nested Cross-Sectional Study.
209. AUTOSTERE: Systematic Search for Scaffold Replacement Opportunities within Structural Databases
210. AGILE: A Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment: An update to the structured summary of a study protocol for a randomised platform trial letter
211. Total and Unbound Doravirine Concentrations and Viral Suppression in CSF.
212. Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study
213. Evidence of HIV pre-exposure or post-exposure prophylaxis (PrEP/PEP) among blood donors: a pilot study, England June 2018 to July 2019
214. Advancing knowledge in perinatal HIV treatment
215. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C(right arrow)T) with reduced concentrations of unboosted atazanavir
216. Longitudinal PKPD biomarkers correlate with treatment outcome in drug sensitive pulmonary tuberculosis; a population pharmacokinetic-pharmacodynamic analysis
217. AGILE-ACCORD: a randomized, multicentre, seamless, adaptive phase I/II platform study to determine the optimal dose, safety and efficacy of multiple candidate agents for the treatment of COVID-19: a structured summary of a study protocol for a randomised platform trial
218. Dolutegravir versus efavirenz when starting HIV therapy in late pregnancy: a randomised controlled trial
219. Plasma NRTI concentration and their associations with liver and renal parameters in people living with HIV
220. An Individual Participant Data Population Pharmacokinetic Meta-Analysis of Drug-drug Interactions between Lumefantrine and Commonly-used Antiretroviral Treatment
221. Polypharmacy and Drug–Drug Interactions in People Living With Human Immunodeficiency Virus in the Region of Madrid, Spain: A Population-Based Study
222. A rapid and sensitive HPLC–MS method for the detection of plasma and cellular rifampicin
223. Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)-A randomized controlled trial of therapeutic drug monitoring and adherence support
224. The Relation of Epicardial Adipose Tissue and Cardiovascular Disease in HIV-Positive and HIV-Negative Patients: The Liverpool HIV-Heart Project
225. Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment
226. Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study
227. A study to assess several different treatments that may be useful for patients with COVID-19
228. Dose prediction for repurposing nitazoxanide in SARS‐CoV‐2 treatment or chemoprophylaxis
229. Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring
230. Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects
231. Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment
232. Drug–drug interactions between antiretrovirals and drugs used in the management of neglected tropical diseases: important considerations in the WHO 2020 Roadmap and London Declaration on Neglected Tropical Diseases
233. Global patient safety and antiretroviral drug–drug interactions in the resource-limited setting
234. Chapter 19: Interactions between Antituberculosis and Antiretroviral Agents
235. Pharmacokinetic drug interactions with nevirapine
236. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glyvoprotein expression in peripheral blood mononuclear cells in vitro
237. Evidence of HIV pre-exposure or post-exposure prophylaxis (PrEP/PEP) among blood donors: a pilot study, England June 2018 to July 2019.
238. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults
239. Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults
240. Ageing with HIV: medication use and risk for potential drug–drug interactions
241. Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals
242. Lopinavir/ritonavir population pharmacokinetics in neonates and infants
243. Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers
244. Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin
245. Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis
246. Safety perspectives on presently considered drugs for the treatment of COVID‐19
247. Limited Utility of Cardiovascular Risk Scores for People Living with HIV in Malawi
248. Drug interactions: a review of the unseen danger of experimental COVID-19 therapies
249. Inflammatory Phenotypes Predict Changes in Arterial Stiffness Following Antiretroviral Therapy Initiation
250. Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.